SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Parabolic Drugs in demand on commissioning new sterile plant

30 Mar 2012 Evaluate

Parabolic Drugs is currently trading at Rs. 29.10, up by 0.40 points or 1.39% from its previous closing of Rs. 28.70 on the BSE.

The scrip opened at Rs. 29.00 and has touched a high and low of Rs. 29.65 and Rs. 29.00 respectively. So far 6755 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 52.70 on 21-Apr-2011 and a 52 week low of Rs. 25.90 on 30-Aug-2011.

Last one week high and low of the scrip stood at Rs. 34.40 and Rs. 28.10 respectively. The current market cap of the company is Rs. 180.72 crore.

The promoters holding in the company stood at 39.17% while Institutions and Non-Institutions held 22.58% and 38.24% respectively. 

Parabolic Drugs has successfully commissioned its new sterile plant at its Cephalosporin facility located in Derabassi, Punjab. The newly commissioned plant will be the ninth plant in the facility and will add to the capacities for manufacturing sterile drugs.

The plant is constructed with the installation of BADO make machinery which is a completely closed processing system, to enhance the sterility assurance through avoidance of contamination through least human intervention. This plant is expected to add up to 120 TPA in Cephalosporin Sterile Capacities.

Parabolic Drugs is Chandigarh based contract manufacturer of active pharmaceutical ingredients (APIs). Currently, it has six units at Sundhran, Derabassi, for manufacturing the oral and sterile range of Cephalosporin APIs and intermediates.

Parabolic Drugs Share Price

1.05 0.00 (0.00%)
25-Jan-2021 18:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1693.15
Dr. Reddys Lab 1221.25
Cipla 1230.75
Zydus Lifesciences 939.20
Lupin 2326.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×